• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

180 例脊髓性肌萎缩症 1c-4 型患者的横断面队列研究中贯穿一生的肌肉力量和运动功能。

Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.

机构信息

Department of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht University, Utrecht.

Department of Child Development and Exercise Centre, University Medical Centre Utrecht, Utrecht.

出版信息

Eur J Neurol. 2018 Mar;25(3):512-518. doi: 10.1111/ene.13534. Epub 2018 Feb 2.

DOI:10.1111/ene.13534
PMID:29194869
Abstract

BACKGROUND AND PURPOSE

Natural history studies in spinal muscular atrophy (SMA) have primarily focused on infants and children. Natural history studies encompassing all age groups and SMA types are important for the interpretation of treatment effects of recently introduced survival motor neuron gene-augmenting therapies.

METHODS

We conducted a cross-sectional study to investigate muscle strength, Hammersmith Functional Motor Scale (Expanded) score and the patterns of muscle weakness in relation to age and SMA type.

RESULTS

We included 180 patients with SMA types 1-4 in the age range 1-77.5 years with median disease duration of 18 (range 0-65.8) years. With the exception of the early phases of disease in which children with SMA types 2 and 3 may achieve new motor skills and show a temporary increase in muscle strength, cross-sectional data suggested that declining muscle strength and loss of motor skills over time are characteristic of all SMA types. Mean loss of strength was at least 1 point on the Medical Research Council score and 0.5 point on the Hammersmith Functional Motor Scale (Expanded) score per year. Trend lines compatible with deterioration of motor function and muscle strength started in childhood and continued into adulthood. The age at loss of specific motor skills was associated with disease severity. Triceps, deltoid, iliopsoas and quadriceps were the weakest muscles in all patients. Hierarchical cluster analysis did not show a segmental distribution of muscle weakness as suggested previously.

CONCLUSIONS

Progressive muscle weakness and loss of motor function are characteristic of all SMA types and all ages.

摘要

背景与目的

脊髓性肌萎缩症(SMA)的自然史研究主要集中在婴儿和儿童。涵盖所有年龄组和 SMA 类型的自然史研究对于解释最近引入的生存运动神经元基因增强治疗的治疗效果非常重要。

方法

我们进行了一项横断面研究,以调查肌肉力量、汉密尔顿运动功能量表(扩展)评分以及与年龄和 SMA 类型相关的肌肉无力模式。

结果

我们纳入了 180 名 SMA 类型 1-4 患者,年龄在 1-77.5 岁之间,中位病程为 18 年(范围 0-65.8 年)。除了 SMA 类型 2 和 3 的儿童可能获得新的运动技能并表现出肌肉力量的暂时增加的疾病早期阶段外,横断面数据表明,随着时间的推移,肌肉力量的下降和运动技能的丧失是所有 SMA 类型的特征。每年肌肉力量平均下降至少 1 个医学研究委员会评分和 0.5 个汉密尔顿运动功能量表(扩展)评分。与运动功能和肌肉力量恶化相符的趋势线始于儿童期,并持续到成年期。特定运动技能丧失的年龄与疾病严重程度相关。三头肌、三角肌、髂腰肌和股四头肌是所有患者中最弱的肌肉。层次聚类分析并未显示出以前建议的肌肉无力的节段分布。

结论

进行性肌肉无力和运动功能丧失是所有 SMA 类型和所有年龄段的特征。

相似文献

1
Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4.180 例脊髓性肌萎缩症 1c-4 型患者的横断面队列研究中贯穿一生的肌肉力量和运动功能。
Eur J Neurol. 2018 Mar;25(3):512-518. doi: 10.1111/ene.13534. Epub 2018 Feb 2.
2
Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude.SMA IIIb型的自然病史:肌肉力量按可预测的顺序和程度下降。
Neurology. 2008 Aug 26;71(9):644-9. doi: 10.1212/01.wnl.0000324623.89105.c4.
3
Muscle strength and motor function in adolescents and adults with spinal muscular atrophy.青少年和成年脊髓性肌萎缩症患者的肌肉力量和运动功能。
Neurology. 2020 Oct 6;95(14):e1988-e1998. doi: 10.1212/WNL.0000000000010540. Epub 2020 Jul 30.
4
Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III.患有脊髓性肌萎缩症II型和III型的儿童及青少年的肌肉力量和运动功能
Eur J Paediatr Neurol. 2001;5(5):191-8. doi: 10.1053/ejpn.2001.0510.
5
Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study.脊髓性肌萎缩症 II 型和 III 型患者肌肉力量随时间的变化。一项长期随访研究。
Neuromuscul Disord. 2012 Dec;22(12):1069-74. doi: 10.1016/j.nmd.2012.06.352. Epub 2012 Nov 3.
6
Bulbar muscle MRI changes in patients with SMA with reduced mouth opening and dysphagia.SMA 患者张口和吞咽困难时的球部肌肉 MRI 改变。
Neurology. 2014 Sep 16;83(12):1060-6. doi: 10.1212/WNL.0000000000000796. Epub 2014 Aug 13.
7
Measurement of muscle strength with a handheld dynamometer in patients with chronic spinal muscular atrophy.使用手持式测力计测量慢性脊髓性肌萎缩症患者的肌肉力量。
J Rehabil Med. 2010 Mar;42(3):228-31. doi: 10.2340/16501977-0507.
8
Spinal muscular atrophy: survival pattern and functional status.脊髓性肌萎缩症:生存模式与功能状态
Pediatrics. 2004 Nov;114(5):e548-53. doi: 10.1542/peds.2004-0668. Epub 2004 Oct 18.
9
Responsiveness of the motor function measure in patients with spinal muscular atrophy.脊髓性肌萎缩症患者运动功能测量的反应性。
Arch Phys Med Rehabil. 2013 Aug;94(8):1555-61. doi: 10.1016/j.apmr.2013.01.014. Epub 2013 Feb 1.
10
Prospective cohort study of spinal muscular atrophy types 2 and 3.2 型和 3 型脊髓性肌萎缩症的前瞻性队列研究。
Neurology. 2012 Oct 30;79(18):1889-97. doi: 10.1212/WNL.0b013e318271f7e4. Epub 2012 Oct 17.

引用本文的文献

1
Neuronal Pentraxin 2 as a Potential Biomarker for Nusinersen Therapy Response in Adults with Spinal Muscular Atrophy: A Pilot Study.神经元五聚体蛋白2作为成人脊髓性肌萎缩症患者对诺西那生治疗反应的潜在生物标志物:一项初步研究
Biomedicines. 2025 Jul 25;13(8):1821. doi: 10.3390/biomedicines13081821.
2
Rehabilitation management for patients with spinal muscular atrophy: a review.脊髓性肌萎缩症患者的康复管理:综述
Orphanet J Rare Dis. 2025 Jul 10;20(1):352. doi: 10.1186/s13023-025-03888-w.
3
Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy.
脊髓性肌萎缩症青少年及成人长期使用诺西那生钠有效性的系统评价与荟萃分析
Adv Ther. 2025 Jun 27. doi: 10.1007/s12325-025-03260-1.
4
Cost-effectiveness of treatments for presymptomatic newborn patients with spinal muscular atrophy and two or three copies of the survival motor neuron 2 gene in Italy.意大利针对具有2或3份存活运动神经元2基因的脊髓性肌萎缩症症状前新生儿患者的治疗成本效益
Eur J Health Econ. 2025 Jun 26. doi: 10.1007/s10198-025-01806-2.
5
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals.澳大利亚医院对脊髓性肌萎缩症进行新生儿筛查的成本效益分析。
Neurol Ther. 2025 Jun;14(3):1007-1022. doi: 10.1007/s40120-025-00744-8. Epub 2025 Apr 27.
6
[Spinal Muscular Atrophy: The Reality of the Adult Patient in Spain].[脊髓性肌萎缩症:西班牙成年患者的实际情况]
Rev Neurol. 2025 Mar 27;80(2):33462. doi: 10.31083/RN33462.
7
Successful pregnancy of an SMA type 3 sitter on Nusinersen therapy - a case report.接受诺西那生治疗的脊髓性肌萎缩3型患者成功妊娠——病例报告
BMC Neurol. 2025 Jan 4;25(1):8. doi: 10.1186/s12883-024-04005-3.
8
Catecholaminergic dysfunction drives postural and locomotor deficits in a mouse model of spinal muscular atrophy.儿茶酚胺能功能障碍导致脊髓性肌萎缩小鼠模型出现姿势和运动缺陷。
Cell Rep. 2025 Jan 28;44(1):115147. doi: 10.1016/j.celrep.2024.115147. Epub 2025 Jan 2.
9
A self-reported Brazilian registry of 5q-spinal muscular atrophy: data on natural history, genetic characteristics, and multidisciplinary care.一份巴西5q型脊髓性肌萎缩症自我报告登记册:自然病史、遗传特征及多学科护理数据
Arq Neuropsiquiatr. 2024 Dec;82(12):1-9. doi: 10.1055/s-0044-1792096. Epub 2024 Dec 20.
10
Brain magnetic resonance imaging of patients with spinal muscular atrophy type 2 and 3.2 型和 3 型脊肌萎缩症患者的脑部磁共振成像。
Neuroimage Clin. 2024;44:103708. doi: 10.1016/j.nicl.2024.103708. Epub 2024 Nov 14.